vs

Side-by-side financial comparison of ALEXANDERS INC (ALX) and LIFECORE BIOMEDICAL, INC. \DE\ (LFCR). Click either name above to swap in a different company.

ALEXANDERS INC is the larger business by last-quarter revenue ($53.3M vs $31.1M, roughly 1.7× LIFECORE BIOMEDICAL, INC. \DE\). On growth, LIFECORE BIOMEDICAL, INC. \DE\ posted the faster year-over-year revenue change (-4.5% vs -4.7%). Over the past eight quarters, LIFECORE BIOMEDICAL, INC. \DE\'s revenue compounded faster (-0.1% CAGR vs -6.9%).

Alexander's, Inc. is a real estate investment trust that owns 7 properties in New York metropolitan area, including 731 Lexington Avenue, the headquarters of Bloomberg L.P. It is controlled by Vornado Realty Trust. It was founded by George Farkas and Louis Schwadron in 1928.

LIFECORE BIOMEDICAL, INC. is a biomedical firm focused on developing and manufacturing high-quality hyaluronic acid-based biomaterials. It operates three core segments: medical application products, pharmaceutical solutions, and personal care ingredients, with main markets spanning North America, Europe and the Asia-Pacific, supplying to leading medical device, pharmaceutical and cosmetic brand partners.

ALX vs LFCR — Head-to-Head

Bigger by revenue
ALX
ALX
1.7× larger
ALX
$53.3M
$31.1M
LFCR
Growing faster (revenue YoY)
LFCR
LFCR
+0.3% gap
LFCR
-4.5%
-4.7%
ALX
Faster 2-yr revenue CAGR
LFCR
LFCR
Annualised
LFCR
-0.1%
-6.9%
ALX

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
ALX
ALX
LFCR
LFCR
Revenue
$53.3M
$31.1M
Net Profit
$-10.0M
Gross Margin
25.0%
Operating Margin
-9.9%
Net Margin
-32.1%
Revenue YoY
-4.7%
-4.5%
Net Profit YoY
-52.0%
EPS (diluted)
$0.75
$-0.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALX
ALX
LFCR
LFCR
Q4 25
$53.3M
Q3 25
$53.4M
$31.1M
Q2 25
$51.6M
Q1 25
$54.9M
$35.2M
Q4 24
$55.9M
$32.6M
Q3 24
$55.7M
$24.7M
Q2 24
$53.4M
Q1 24
$61.4M
$35.7M
Net Profit
ALX
ALX
LFCR
LFCR
Q4 25
Q3 25
$6.0M
$-10.0M
Q2 25
$6.1M
Q1 25
$12.3M
$-14.8M
Q4 24
$-6.6M
Q3 24
$6.7M
$-16.2M
Q2 24
$8.4M
Q1 24
$16.1M
$15.6M
Gross Margin
ALX
ALX
LFCR
LFCR
Q4 25
Q3 25
25.0%
Q2 25
Q1 25
28.0%
Q4 24
34.0%
Q3 24
21.8%
Q2 24
Q1 24
33.3%
Operating Margin
ALX
ALX
LFCR
LFCR
Q4 25
Q3 25
-9.9%
Q2 25
Q1 25
-25.7%
Q4 24
-6.0%
Q3 24
-46.9%
Q2 24
Q1 24
-2.5%
Net Margin
ALX
ALX
LFCR
LFCR
Q4 25
Q3 25
11.2%
-32.1%
Q2 25
11.9%
Q1 25
22.4%
-42.0%
Q4 24
-20.2%
Q3 24
12.0%
-65.7%
Q2 24
15.7%
Q1 24
26.2%
43.8%
EPS (diluted)
ALX
ALX
LFCR
LFCR
Q4 25
$0.75
Q3 25
$1.16
$-0.29
Q2 25
$1.19
Q1 25
$2.40
$-0.47
Q4 24
$2.39
$-0.25
Q3 24
$1.30
$-0.53
Q2 24
$1.63
Q1 24
$3.14
$0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALX
ALX
LFCR
LFCR
Cash + ST InvestmentsLiquidity on hand
$128.2M
$18.9M
Total DebtLower is stronger
$136.0M
Stockholders' EquityBook value
$109.2M
$-10.5M
Total Assets
$1.1B
$235.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALX
ALX
LFCR
LFCR
Q4 25
$128.2M
Q3 25
$286.1M
$18.9M
Q2 25
$313.0M
Q1 25
$319.9M
$5.4M
Q4 24
$338.5M
$9.5M
Q3 24
$354.8M
Q2 24
$410.9M
Q1 24
$526.3M
Total Debt
ALX
ALX
LFCR
LFCR
Q4 25
Q3 25
$136.0M
Q2 25
Q1 25
$124.9M
Q4 24
$111.3M
Q3 24
$106.3M
Q2 24
Q1 24
$97.1M
Stockholders' Equity
ALX
ALX
LFCR
LFCR
Q4 25
$109.2M
Q3 25
$128.3M
$-10.5M
Q2 25
$145.4M
Q1 25
$163.1M
$2.2M
Q4 24
$176.9M
$15.4M
Q3 24
$190.7M
$-3.9M
Q2 24
$212.5M
Q1 24
$230.1M
$17.7M
Total Assets
ALX
ALX
LFCR
LFCR
Q4 25
$1.1B
Q3 25
$1.3B
$235.2M
Q2 25
$1.3B
Q1 25
$1.3B
$237.7M
Q4 24
$1.3B
$255.4M
Q3 24
$1.4B
$246.8M
Q2 24
$1.5B
Q1 24
$1.4B
$246.2M
Debt / Equity
ALX
ALX
LFCR
LFCR
Q4 25
Q3 25
Q2 25
Q1 25
56.05×
Q4 24
7.20×
Q3 24
Q2 24
Q1 24
5.49×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALX
ALX
LFCR
LFCR
Operating Cash FlowLast quarter
$73.4M
$1.8M
Free Cash FlowOCF − Capex
$25.0K
FCF MarginFCF / Revenue
0.1%
Capex IntensityCapex / Revenue
5.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-16.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALX
ALX
LFCR
LFCR
Q4 25
$73.4M
Q3 25
$-9.3M
$1.8M
Q2 25
$43.6M
Q1 25
$15.7M
$1.2M
Q4 24
$54.1M
$-6.1M
Q3 24
$-5.0M
$-613.0K
Q2 24
$11.5M
Q1 24
$16.8M
$-1.4M
Free Cash Flow
ALX
ALX
LFCR
LFCR
Q4 25
Q3 25
$25.0K
Q2 25
Q1 25
$-4.3M
Q4 24
$-8.6M
Q3 24
$-4.0M
Q2 24
Q1 24
$-7.8M
FCF Margin
ALX
ALX
LFCR
LFCR
Q4 25
Q3 25
0.1%
Q2 25
Q1 25
-12.1%
Q4 24
-26.3%
Q3 24
-16.3%
Q2 24
Q1 24
-21.8%
Capex Intensity
ALX
ALX
LFCR
LFCR
Q4 25
Q3 25
5.6%
Q2 25
Q1 25
15.5%
Q4 24
7.5%
Q3 24
13.9%
Q2 24
Q1 24
17.8%
Cash Conversion
ALX
ALX
LFCR
LFCR
Q4 25
Q3 25
-1.55×
Q2 25
7.12×
Q1 25
1.28×
Q4 24
Q3 24
-0.75×
Q2 24
1.37×
Q1 24
1.04×
-0.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ALX
ALX

Segment breakdown not available.

LFCR
LFCR

Transferred At Point In Time$26.6M85%
Transferred Over Time$4.5M15%

Related Comparisons